Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | TK2 | O00142 | 1/20 | 0.67 |
| ▸ | PYGM | P11217 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idoxuridine SCHEMBL51859 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL5983279 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL5983277 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL9951400 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL6519051 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL13252710 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL2918701 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL4426782 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL21585076 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Idoxuridine SCHEMBL10015658 | 1.00 | TK1 (1.00) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3225 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-12612662-B2 | DNA repair site detection for personal genomics, epigenomics, and gene therapy | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2026-04-28 | — | — | US | claimed |
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PREC BIOLOGICS INC (US) | 2026-03-26 | — | — | US | claimed |
| US-20250302857-A1 | Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation | SHUTTLE PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| US-12357650-B2 | Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation | SHUTTLE PHARMACEUTICALS, INC. (US) | 2025-07-15 | — | — | US | claimed |
| EP-4514819-A1 | METHOD OF EVALUATING SMALL MOLECULE DISTRIBUTION USING TELLUROPHENE ANALOGUES | The Governing Council of the University of Toronto (CA) | 2025-03-05 | — | — | EP | claimed |
| EP-4499710-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | Precision Biologics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| US-20240400714-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREG CELLS | PREC BIOLOGICS INC (US) | 2024-12-05 | — | — | US | claimed |
| US-20240384003-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | PREC BIOLOGICS INC (US) | 2024-11-21 | — | — | US | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| EP-0126684-B1 | DRUG DELIVERY SYSTEM UTILIZING THERMOSETTING GELS | MERCK & CO. INC. (US) | 1991-08-28 | — | — | EP | claimed |
| EP-0310645-A1 | COMPOUNDS USEFUL PARTICULARLY FOR RADIOTHERAPY OR IMAGING OF CANCER. | IRECELLTARG S A (BE) | 1989-04-12 | — | — | EP | claimed |
| US-4816570-A | Biologically reversible phosphate and phosphonate protective groups | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-28 | — | — | US | claimed |
| WO-1988007986-A2 | COMPOUNDS USEFUL PARTICULARLY FOR RADIOTHERAPY OR IMAGING OF CANCER | IRE-CELLTARG S.A. (BE) | 1988-10-20 | — | — | WO | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474748-A | ANTIBIOTICS, FUNGICIDES, ANTISEPTICS | JOHNSON & JOHNSON (US) | 1984-10-02 | — | — | US | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |